Ipatimup

RESEARCHDIAGNOSTICSTRANSLATIONOUTREACH

Jorge Lima

Name: Jorge Lima

E-mail: jlima@ipatimup.pt

Jorge Lima

Member of

Advisory Board Member of Ipatimup Innovation

Consultant of Ipatimup Diagnostics

Director of Ipatimup Translational Research

Researcher of Cancer Signalling & Metabolism

Short CV

I am a currently a Researcher at Ipatimup, where I have been mainly dedicated to the study of cancer metabolism. I hold an undergraduate degree in Biology and a PhD from the Medical Faculty of University of Porto. My doctoral research focused on the role of metabolic enzymes in inherited neoplasias. As a post-doc, I started building cell line models for mitochondrial deficiency, in collaboration between Ipatimup and the Roswell Park Cancer Institute, Buffalo, USA. Over the years I have also developed collaborations at the clinical level, particularly with the University Hospital and the Oncology Institute in Porto. I have supervised two Master students to completion and I am currently supervising two Master students, one PhD student and co-supervising one PhD student. My scientific research has resulted in over 20 publications in peer-reviewed international journals, that have given rise to 774 citations (741 without self-citation; h-index 11; source: Web of Science). I am currently also part of the Translational Research Unit at Ipatimup, where we aim to capitalize the scientific expertise at Ipatimup and to develop collaborations and strategic alliances with Pharma and Biotech companies.

Highlights

My main area of research is the metabolic reprogramming of cancer cells and how this may contribute to cancer development. My interest in this subject came from previous studies on the particular features of the so-called Hürthle cell thyroid tumours which accumulate large amounts of abnormal mitochondria in the cytoplasm; these tumours were found to harbor somatic mutations in the mitochondrial DNA that presumably result in loss of function of the oxidative phosphorylation system (OXPHOS). In subsequent studies I have addressed the role of the nuclear-encoded mitochondrial enzyme succinate dehydrogenase (SDH) in the development of peripheral nervous system tumours such as paragangliomas (PGL) and pheochromocytomas (PCC), as well as the development of medullary thyroid tumours. The presence of germline loss-of-function mutations in SDH (Krebs cycle enzyme) subunits in inherited PGL and PCC reveals that altered cell metabolism is capable of inducing tumour development

Supervisor of

Joana Peixoto, Assistant Researcher
Post-Doc Researcher

Paulo Canedo, Team Coordinator
Unit Manager

PI (running)

Implementação de Biomarcadores Moleculares para medicina de precisão com doentes com tumores cerebrais pediátricos

PI (closed)

”Bioengineered nanocarriers for targeted drug delivery in glioblastoma multiforme therapy

Desenvolvimento de biomarcadores em tumores sólidos

First Author

1. Celestino R, Lima J, Faustino A, Máximo V, Gouveia A, Vinagre J, Soares P, Lopes JM

A novel germline SDHB mutation in a gastrointestinal stromal tumor patient without bona fide features of the Carney-Stratakis dyad. Familial cancer 11: 189-94, 2012. [Article]

doi: 10.1007/s10689-011-9499-x PMID: 22160509.

1.9

2. Lima J, Feijão T, Ferreira da Silva A, Pereira-Castro I, Fernandez-Ballester G, Máximo V, Herrero A, Serrano L, Sobrinho-Simões M, Garcia-Rostan G

High frequency of germline succinate dehydrogenase mutations in sporadic cervical paragangliomas in northern Spain: mitochondrial succinate dehydrogenase structure-function relationships and clinical-pathological correlations. The Journal of clinical endocrinology and metabolism 92: 4853-64, 2007. [Article]

doi: 10.1210/jc.2007-0640 PMID: 17848412.

5.5

3. Lima J, Trovisco V, Soares P, Máximo V, Magalhães J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, Jeremiah S, Thomas G, Williams D, Sobrinho-Simões M

Reply to: Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer letters 230: 149-50, 2005. [Letter]

doi: 10.1016/j.canlet.2004.10.053 PMID: 16253771.

3.0

4. Lima J, Trovisco V, Soares P, Máximo V, Magalhães J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, Jeremiah S, Thomas G, Williams D, Sobrinho-Simões M

BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. The Journal of clinical endocrinology and metabolism 89: 4267-71, 2004. [Article]

doi: 10.1210/jc.2003-032224 PMID: 15356020.

130

5.8

5. Lima J, Teixeira-Gomes J, Soares P, Máximo V, Honavar M, Williams D, Sobrinho-Simões M

Germline succinate dehydrogenase subunit D mutation segregating with familial non-RET C cell hyperplasia. The Journal of clinical endocrinology and metabolism 88: 4932-7, 2003. [Article]

PMID: 14557476.

5.9

6. Lima J, Máximo V, Soares P, Sobrinho-Simões M

Alterations of the SDHD gene locus in midgut carcinoids. Genes, chromosomes & cancer 36: 424, 2003. [Letter]

doi: 10.1002/gcc.10147 PMID: 12619155.

4.2

7. Lima J, Máximo V, Soares P, Williams D, Bogdanova T, Thomas GA, Sobrinho-Simões M

Re: Lohrer,H.D., Hieber,L. and Zitzelsberger,H. (2002) Differential mutation frequency in mitochondrial DNA from thyroid tumours. Carcinogenesis, 23, 1577-1582. Carcinogenesis 24: 1155, 2003. [Letter]

doi: 10.1093/carcin/bgg050 PMID: 12807747.

4.7

Senior Author

1. Bastos AGP, Carvalho B, Silva R, Leitão D, Linhares P, Vaz R, Lima J

Endoglin (CD105) and proliferation index in recurrent glioblastoma treated with anti-angiogenic therapy. Frontiers in oncology 12: 910196, 2022. [Article]

doi: 10.3389/fonc.2022.910196 PMID: 36147918.

5.7 (*)

2. Carvalho B, Lopes JM, Silva R, Peixoto J, Leitão D, Soares P, Fernandes AC, Linhares P, Vaz R, Lima J

The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab. Scientific reports 11: 6067, 2021. [Article]

doi: 10.1038/s41598-021-85385-1 PMID: 33727583.

4.4 (*)

3. Peixoto J, Janaki-Raman S, Schlicker L, Schmitz W, Walz S, Winkelkotte AM, Herold-Mende C, Soares P, Schulze A, Lima J

Integrated Metabolomics and Transcriptomics Analysis of Monolayer and Neurospheres from Established Glioblastoma Cell Lines. Cancers 13: ., 2021. [Article]

doi: 10.3390/cancers13061327 PMID: 33809510.

6.6 (*)

4. Peixoto J, Lima J

Metabolic traits of cancer stem cells. Disease models & mechanisms 11: ., 2018. [Review]

doi: 10.1242/dmm.033464 PMID: 29991569.

4.4 (*)

5. Batista R, Cruvinel-Carloni A, Vinagre J, Peixoto J, Catarino TA, Campanella NC, Menezes W, Becker AP, de Almeida GC, Matsushita MM, Clara C, Neder L, Viana-Pereira M, Honavar M, Castro L, Lopes JM, Carvalho B, Vaz RM, Máximo V, Soares P, Sobrinho-Simões M, Reis RM, Lima J

The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism. International journal of cancer 139: 414-23, 2016. [Article]

doi: 10.1002/ijc.30057 PMID: 26914704.

6.5

6. Amorim-Pires D, Peixoto J, Lima J

Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas. Cytogenetic and genome research 150: 227-241, 2016. [Review]

doi: 10.1159/000457479 PMID: 28231563.

1.4

7. Nunes JB, Peixoto J, Soares P, Maximo V, Carvalho S, Pinho SS, Vieira AF, Paredes J, Rego AC, Ferreira IL, Gomez-Lazaro M, Sobrinho-Simoes M, Singh KK, Lima J

OXPHOS dysfunction regulates integrin-ß1 modifications and enhances cell motility and migration. Human molecular genetics 24: 1977-90, 2015. [Article]

doi: 10.1093/hmg/ddu612 PMID: 25504047.

6.0

8. Martins RG, Nunes JB, Máximo V, Soares P, Peixoto J, Catarino T, Rito T, Soares P, Pereira L, Sobrinho-Simões M, Santos AP, Couto J, Henrique R, Matos-Loureiro J, Dias P, Torres I, Lima J

A founder SDHB mutation in Portuguese paraganglioma patients. Endocrine-related cancer 20: L23-6, 2013. [Letter]

doi: 10.1530/ERC-12-0399 PMID: 24092654.

4.9

@ 2014 Ipatimup Institute of Molecular Pathology and Immunology of the University of Porto